<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783886</url>
  </required_header>
  <id_info>
    <org_study_id>15161</org_study_id>
    <nct_id>NCT01783886</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement</brief_title>
  <acronym>VIVID EAST</acronym>
  <official_title>A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the
      best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy
      study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Greater Than Equal (&gt;=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF</measure>
    <time_frame>Baseline up to week 52</time_frame>
    <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">381</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection 2Q4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection 2Q8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macular Laser Photocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).</description>
    <arm_group_label>Intravitreal Aflibercept Injection 2Q4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).</description>
    <arm_group_label>Intravitreal Aflibercept Injection 2Q8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Macular Laser Photocoagulation</intervention_name>
    <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.</description>
    <arm_group_label>Macular Laser Photocoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults â‰¥ 18 years with type 1 or 2 diabetes mellitus

          -  Subjects with diabetic macular edema (DME) secondary to diabetes mellitus involving
             the center of the macula in the study eye

          -  Decrease in vision determined to be primarily the result of DME in the study eye

          -  Best-corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS)
             letter score of 73 to 24 (20/40 to 20/320) in the study eye

        Exclusion Criteria:

          -  Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day
             1

          -  More than 2 previous macular laser treatments in the study eye

          -  Previous use of intraocular or periocular corticosteroids in the study eye within 120
             days of Day 1

          -  Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium,
             bevacizumab, ranibizumab etc.) within 90 days of Day 1

          -  Active proliferative diabetic retinopathy (PDR) in the study eye

          -  Uncontrolled diabetes mellitus, as defined by HbA1c &gt;12%

          -  Only 1 functional eye even if that eye is otherwise eligible for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510064</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>2000080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>105062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <results_first_submitted>March 6, 2016</results_first_submitted>
  <results_first_submitted_qc>March 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2016</results_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>DME</keyword>
  <keyword>VEGF Trap-Eye</keyword>
  <keyword>best-corrected visual acuity (BCVA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at centers in China, Hong Kong, South Korea, and Russian Federation between 18 February 2013 (first participant first visit) and 09 March 2015 (last participant last visit) (data cut-off date).</recruitment_details>
      <pre_assignment_details>Overall 539 participants were screened, of them 381 participants were randomized, and 378 participants were allocated to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravitreal Aflibercept Injection 2Q4</title>
          <description>Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Intravitreal Aflibercept Injection 2Q8</title>
          <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Macular Laser Photocoagulation</title>
          <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent by participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravitreal Aflibercept Injection 2Q4</title>
          <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) 2Q4 over 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Intravitreal Aflibercept Injection 2Q8</title>
          <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Macular Laser Photocoagulation</title>
          <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="378"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="10.3"/>
                    <measurement group_id="B2" value="57.6" spread="10.1"/>
                    <measurement group_id="B3" value="58.8" spread="10.5"/>
                    <measurement group_id="B4" value="58.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Geographic region</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Asia-Pacific (Hong Kong, Korea)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)</title>
        <description>Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>Full analysis set (FAS) included all randomized participants who received any study treatment, had a baseline measurement of BCVA, and had at least 1 post-baseline assessment of BCVA. FAS with assessment for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)</title>
          <description>Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment.</description>
          <population>Full analysis set (FAS) included all randomized participants who received any study treatment, had a baseline measurement of BCVA, and had at least 1 post-baseline assessment of BCVA. FAS with assessment for this outcome measure.</population>
          <units>Letters correctly read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="8.4"/>
                    <measurement group_id="O2" value="12.8" spread="9.5"/>
                    <measurement group_id="O3" value="-0.2" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.1</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.9</ci_lower_limit>
            <ci_upper_limit>17.2</ci_upper_limit>
            <estimate_desc>Least Square (LS) mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.2</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF</title>
        <description>Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF</title>
          <description>Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.</description>
          <population>FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9"/>
                    <measurement group_id="O2" value="62.7"/>
                    <measurement group_id="O3" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>47.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.0</ci_lower_limit>
            <ci_upper_limit>59.9</ci_upper_limit>
            <estimate_desc>Cochran-Mantel-Haenszel (CMH). The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>39.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.3</ci_lower_limit>
            <ci_upper_limit>52.1</ci_upper_limit>
            <estimate_desc>The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF</title>
        <description>Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF</title>
          <description>Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.</description>
          <population>FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="36.5"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>31.1</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.2</ci_lower_limit>
            <ci_upper_limit>43.0</ci_upper_limit>
            <estimate_desc>The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>24.3</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.6</ci_lower_limit>
            <ci_upper_limit>35.9</ci_upper_limit>
            <estimate_desc>The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Greater Than Equal (&gt;=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF</title>
        <description>ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Greater Than Equal (&gt;=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF</title>
          <description>ETDRS DRSS: None (level 10); Mild to moderate nonproliferative diabetic retinopathy (DR) (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)</description>
          <population>FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="62.3"/>
                    <measurement group_id="O3" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>39.1</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.0</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
            <estimate_desc>The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH adjusted difference</param_type>
            <param_value>40.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.6</ci_lower_limit>
            <ci_upper_limit>53.7</ci_upper_limit>
            <estimate_desc>The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF</title>
        <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>FAS with assessment for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
          <population>FAS with assessment for this outcome measure.</population>
          <units>micrometer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-238.7" spread="172.5"/>
                    <measurement group_id="O2" value="-234.7" spread="160.8"/>
                    <measurement group_id="O3" value="-109.3" spread="206.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-130.5</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-171.2</ci_lower_limit>
            <ci_upper_limit>-89.9</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-131.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-172.8</ci_lower_limit>
            <ci_upper_limit>-89.9</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF</title>
        <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>FAS with assessment for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF</title>
          <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.</description>
          <population>FAS with assessment for this outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="23.86"/>
                    <measurement group_id="O2" value="7.28" spread="22.95"/>
                    <measurement group_id="O3" value="0.04" spread="24.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0364</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.78</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>11.97</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.87</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>12.94</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF</title>
        <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.</description>
        <time_frame>Baseline up to week 52</time_frame>
        <population>FAS with assessment for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept Injection 2Q4</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Aflibercept Injection 2Q8</title>
            <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Macular Laser Photocoagulation</title>
            <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF</title>
          <description>The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.</description>
          <population>FAS with assessment for this outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="22.36"/>
                    <measurement group_id="O2" value="10.25" spread="21.44"/>
                    <measurement group_id="O3" value="0.04" spread="23.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2688</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.81</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>8.53</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.01</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.64</ci_lower_limit>
            <ci_upper_limit>13.37</ci_upper_limit>
            <estimate_desc>LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of study treatment up to 52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intravitreal Aflibercept Injection 2Q4</title>
          <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Intravitreal Aflibercept Injection 2Q8</title>
          <description>Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Macular Laser Photocoagulation</title>
          <description>Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Right ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Renal osteodystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Malignant lymphoid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Retinal aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Visual acuity tests abnormal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

